$ABBV · AbbVie Inc.

AbbVie Inc. filed a current report on Form 8-K disclosing that Jennifer L. Davis, a Class II director, notified the company’s board of directors on October 28, 2026, of her intent to resign from the board. Her resignation became effective on November 2, 2026. The filing states that she stepped down in light of her recent appointment as Chief Executive Officer at Align Technology, Inc.

AbbVie noted that Davis’s resignation as a director was not the result of any dispute or disagreement with the company on any matter relating to its operations, policies, or practices. The report was signed by Perry C. Siatis, AbbVie’s Executive Vice President, General Counsel and Secretary, on November 2, 2026.